Symposium
Tox 21 and New Approach Methodology (NAMs): Using Emerging Technologies to Improve Translational Research and Safety Assessment Predictions (jointly by SOT-NorCal & PBSS)
Speakers:
Kathryn Page (Clorox); Shichang Miao (ChemoCentryx); Thomas Hartung (The Bloomberg School of Public Health); Emily Reinke (U.S. Army Public Health Center); Suzanne Fitzpatrick (FDA); Pamela Lein (UC Davis); Ellen Berg (Eurofins); Will Proctor (Genentech)
Organizers:
Date:
2019-04-25
Time:
8:30-17:00 Pacific Time
Registration fee:
(USD): Regular (with lunch): $60; Students & Postdocs (with lunch): $0
Location:
South San Francisco Conference Center
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2019-04-23
(it will close sooner if the seating cap is reached)
About the Topic
Preliminary Agenda
Morning Session
7:30 am – 8:30 am Registration & Breakfast
8:30 am – 8:45 am Opening message from The NorCal & PBSS Presidents - Kathryn Page, PhD, DABT, Clorox; Shichang Miao, PhD, ChemoCentryx
8:45 am – 9:30 am Plenary Speaker: Alternative Methods for the 21st Century - Thomas Hartung, PhD, Johns Hopkins Bloomberg School of Public Health
9:30 am – 10:15 am From Experimental Concept to Regulatory Acceptance: The Success of Alternative Methods in Skin Sensitization Testing - Emily Reinke, PhD, DABT, U.S. Army Public Health Center
10:15 am – 10:30 am Coffee Break
10:30 am – 11:15 am Consumer Product Safety Assessment: An Alternative Approach - Kathryn Page, PhD, DABT, Clorox
11:15 am – 12:00 pm Predictive Toxicology for Regulatory Decisions: Implementing New Approaches at FDA - Suzanne Fitzpatrick, PhD, FDA
12:00 pm – 1:30 pm Lunch Break: Lunch with Experts, Posters
Afternoon Session
1:30 pm – 1:45 pm Chapter announcements and acknowledgements
1:45 am – 2:05 am NorCal Student Award presentation: TBD
2:05 pm – 2:45 pm In Vitro and Alternative Models of Neurotoxicity: Opportunities and Challenges for Neurotoxicity Testing - Pamela Lein, PhD, DABT, UC Davis
2:45 pm – 3:00 pm Coffee Break
3:00 pm – 3:45 pm Applying Human-based Phenotypic Profiling in Early Drug Discovery - Ellen Berg, PhD, Eurofins
3:45 pm – 4:30 pm Industry Perspective on Evaluating, Qualifying, and Implementing Complex In Vitro Models to Support Drug Discovery - Will Proctor, PhD, DABT, Genentech
4:30 pm – 6:00 pm Reception & Networking
2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
|
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
|
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
|
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|